Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

B-044

Supelco

Buprenorphine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C29H41NO4
Número de CAS:
52485-79-7
Peso molecular:
467.64
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1

InChI key

RMRJXGBAOAMLHD-IHFGGWKQSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

A Certified Spiking Solution® suitable for GC/MS or LC/MS applications in pain prescription monitoring, forensic testing, or clinical toxicology.

Buprenorphine is a semi-synthetic opioid that shows partial agonistic activity towards the μ-opioid receptor and antagonistic activity towards the kappa opioid receptor. And even though it is similar to morphine, it is more potent than morphine. The drug is sold under numerous trade names such as Suboxone®, Subutex®, and Temgesic.

Application

The certified reference solution (CRM) in solution can also be used as follows:
  • Multi-residue analysis of buprenorphine, norbuprenorphine, and naloxone in the fingernails and urine samples of previous heroin users under an opioid substitution therapy by solid-liquid or solid-phase extraction combined with liquid chromatography-mass spectrometry (LC-MS) for analysis
  • Liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) based separation and determination of naloxone, buprenorphine, and norbuprenorphine in human plasma samples following their single-step liquid-liquid extraction (LLE)
  • Development of nanocomposite rhodium nanoparticles-mesoporous carbon (RhNPs-MC) for their deposition on glassy carbon electrode (GCE) to compose an electrochemical sensor for the measurement of morphine and buprenorphine in pharmaceutical formulations and human serum samples using differential pulse voltammetry (DPV)
  • Study of human blood plasma samples for the quantitative analysis of buprenorphine and naloxone by liquid chromatography (LC) coupled to high-resolution time-of-flight mass spectrometry (HR-Q-TOF-MS)
  • Simultaneous determination of buprenorphine, norbuprenorphine, and their glucuronides from human urine samples by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS)

Features and Benefits

  • Fully characterized under ISO/IEC 17025 and ISO 17034 accreditation
  • Accompanied with a comprehensive Certificate of Analysis (CoA) with data on stability, homogeneity, accuracy of concentration, uncertainty, and traceability
  • Rigorously tested through real-time stability studies to ensure accuracy and shelf life
  • Gravimetrically prepared using qualified precision balances to ensure minimal uncertainty
  • Flame sealed under argon into ampoules for long-term shelf life
  • Offered in a convenient, DEA-exempt format to improve laboratory efficiency

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Related product

Referencia del producto
Descripción
Precios

B-035

Buprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphine-D4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-902

Buprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphine-D4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

Norbuprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-044S

Buprenorphine solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

K Wahle et al.
MMW Fortschritte der Medizin, 155 Suppl 1, 25-31 (2013-05-18)
Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic
Jatinder Mohan Chawla et al.
Journal of opioid management, 9(1), 35-41 (2013-05-28)
Tramadol is a synthetic opiate and a centrally acting weak m-opioid receptor agonist. The potential advantages of tramadol include ease of administration, low abuse potential, and being nonscheduled. This study compared tramadol and buprenorphine for controlling withdrawal symptoms in patients
E J Love et al.
The Veterinary record, 172(24), 635-635 (2013-06-06)
Buprenorphine has recently obtained UK Marketing Authorisation for horses. The analgesic effects are long lasting, and have considerable potential for postoperative pain relief. This observer blinded, randomised study aimed to evaluate postsurgical analgesia in ponies premedicated with buprenorphine prior to
O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
P M J Clement et al.
Acta clinica Belgica, 68(2), 87-91 (2013-08-24)
Despite guidelines and recommendations, a large proportion of patients with cancer still have inadequate pain control. Transdermal opioid administration can overcome problems such as swallowing and compliance, because only one application every three days is needed. Transdermal buprenorphine was documented
Ver todos los artículos relacionados

Artículos

Benefits of Ascentis Express Phenyl-Hexyl over Biphenyl for the Separation of Pain Management Opiates

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocolos

LC/MS (TOF) Analysis of Drugs and Their Glucuronide Metabolites in Urine on Titan™ C18 After Solid Phase Extraction (SPE) Using Supel™-Select SCX, β-Glucuronidase Enzyme Digestion

-THC solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico